Nomlabofusp Data To Be Shown at Ataxia Congress
Larimar will present longer-term interim and biomarker findings for the research-stage drug in Atlanta on November 12, 2026.
Updated on Nov. 5, 2026 in Biotech

Larimar Therapeutics will present three poster presentations on its investigational drug nomlabofusp at the International Congress for Ataxia Research 2026, held November 10-13, 2026, in Atlanta, Georgia. The posters will cover previously disclosed interim clinical data from an ongoing open-label study of long-term daily dosing, plus new plasma lipid and gene expression analyses in participants with Friedreich's ataxia. Nomlabofusp is research-stage: the presentations report study observations, not an approved therapy.
Why it matters
The congress is a scheduled venue where a clinical-stage company will show longer-term observations in Friedreich's ataxia, a rare inherited neurodegenerative disease. Adding lipid and gene expression profiles alongside clinical interim data shows an attempt to characterize biological effects beyond symptoms, which matters for how the field evaluates candidates in rare disease.
The evidence is interim data from an ongoing open-label study, combined with new plasma lipid and gene expression analyses in Friedreich's ataxia participants. The source does not disclose numerical results or comparators, and the findings will not be characterized until the posters are presented.
The players
Larimar Therapeutics
A clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, focused on complex rare diseases and trading on Nasdaq as LRMR.
The details
Nomlabofusp is an investigational drug being studied for Friedreich's ataxia, an inherited disease that damages nerve function and coordination over time. The three posters will present interim observations from patients taking the drug daily over the long term, along with plasma lipid profiles (fat molecules measured in blood) and gene expression patterns (which genes are switched on or off in cells). Gene expression analysis tells researchers how a treatment may be changing biological activity, not just symptoms. All three posters will be displayed at the Cobb Convention Center during the congress.
Timeline
November 10-13, 2026: International Congress for Ataxia Research 2026 in Atlanta, Georgia.
November 12, 2026, 6:30-7:30 p.m. ET: Poster Session Day 3, featuring all three Larimar presentations.
The Tech Race
The presentations join other ataxia research programs competing to show biomarker and clinical evidence in Friedreich's ataxia, where few disease-modifying approaches are approved. Larimar is positioning its data at a specialist venue that draws the researchers and clinicians who evaluate such candidates.
For people with Friedreich's ataxia and their families, the presentations are a source of early information on whether nomlabofusp may warrant further study, but the drug is not available outside trials. No pricing, access timeline, or approval date has been announced.
The takeaway
The key trajectory is whether interim biomarker and clinical data from nomlabofusp hold up in the poster presentations on November 12, 2026. Watch the Poster Session Day 3 materials and any follow-on data release for signs of consistent effect.
What happens next
The three Larimar posters will be presented at Poster Session Day 3 on November 12, 2026, from 6:30 to 7:30 p.m. ET at the Cobb Convention Center in Atlanta.
Further reading
For broader context on drug development in rare neurological conditions, see Biotech coverage across the United States.
More information
Visit the Larimar Therapeutics company website for details on the company and its nomlabofusp program.
Source note: This article includes information reported by The Manila times.





